section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Complicated Skin/Skin Structure Infections

Renal Impairment

Staphylococcus aureus Bacteremia/Right-Sided Infective Endocarditis

Renal Impairment

Staphylococcus aureus Bacteremia

US Brand Names

Cubicin, Cubicin RF

Action

  • Causes rapid depolarization of membrane potential following binding to bacterial membrane; this results in inhibition of protein, DNA, and RNA synthesis.
Therapeutic effects:
  • Death of bacteria with resolution of infection.

Spectrum:

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: cyclic lipopeptide antibacterial agents

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Protein Binding: 92%.

Metabolism/Excretion: Metabolism not known; mostly excreted by kidneys.

Half-Life: 8.1 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
IVrapidend of infusion24 hr

Patient/Family Teaching

  • Explain the purpose and side effects of daptomycin. Advise patient to read Medication Guide before starting and periodically during therapy in case of changes.
  • Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional immediately if weakness, numbness, or tingling in forearms and lower legs or signs and symptoms of eosinophilic pneumonia or DRESS occur.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications. Instruct patient to avoid using HMG-CoA reductase inhibitors (cholesterol-lowering agents such as atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin) unless approved by health care professional, as concurrent use with daptomycin may risk of myopathy.
  • Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Monitor breastfed infants exposed to daptomycin for GI disturbances.

Pronunciation

dap-to-MYE-sin

Code

NDC Code